Endometriosis affects around 10% of women of reproductive age worldwide, yet treatment options remain limited. Hormonal therapies and surgery can help manage symptoms, but they do not work for everyone and recurrence remains a significant challenge.

A new investigational therapy, ENDO-205, is now moving into early clinical development, offering a potentially different approach.

Developed as a first-in-class, non-hormonal peptide, ENDO-205 is designed to target endometriosis lesions and trigger apoptosis – the body’s natural process of programmed cell death – within diseased tissue.

In 2026, the US Food and Drug Administration (FDA) cleared the company’s Investigational New Drug (IND) application, allowing ENDO-205 to progress towards first-in-human clinical trials.

A different approach to endometriosis

The science behind the approach is based on an established feature of endometriosis: abnormal cells within lesions can show increased resistance to apoptosis, helping them survive and persist.

ENDO-205 is designed to exploit this biology, with the aim of selectively triggering cell death within endometriotic lesions rather than relying on hormonal suppression.

That distinction is important. Current treatments largely work by managing the hormonal environment associated with endometriosis. A treatment capable of targeting the lesions themselves could represent a different therapeutic strategy.

However, the distinction between an interesting scientific concept and a clinically proven treatment is equally important.

What do we know – and what don’t we know?

The FDA’s IND clearance is an important development milestone, but it does not mean that ENDO-205 has been shown to be safe or effective in patients.

The programme is only now entering first-in-human clinical development. The initial studies are expected to focus on safety, tolerability and dosing rather than demonstrating whether the treatment can reduce symptoms or eliminate lesions in people with endometriosis.

There are also limitations to the evidence currently available. Reported preclinical results suggesting lesion elimination have come from the developer and have not yet been established through peer-reviewed human clinical research.

A number of questions therefore remain unanswered:

  • Does ENDO-205 reduce endometriosis lesions or symptoms in humans?
  • How selective is its effect within the complex environment of the human body?
  • What dose is both safe and effective?
  • What are the implications for fertility and longer-term health?
  • If it works, how durable is the effect?
  • And ultimately, can the treatment progress successfully through clinical development and regulatory review?

Why it is worth watching

Endometriosis remains an area of significant unmet medical need, and research into treatments that move beyond hormonal suppression is particularly interesting.

ENDO-205 is still at an early stage, so it is too soon to know whether its proposed mechanism will translate into a meaningful clinical benefit. But its progression into human trials will provide an important opportunity to test whether a lesion-targeted, non-hormonal approach can deliver what the preclinical science suggests.

For now, ENDO-205 remains an investigational therapy. It is not an approved treatment for endometriosis and is not available to buy or prescribe.

As clinical data emerge, the focus will move from what the science suggests may be possible to what the evidence demonstrates is safe, effective and clinically meaningful.

Back to News + Insights